Loading the session
Loading the session
Loading instrument
$34.66
+0.71%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 4 Nov 2026 close of $34.42 was 13.2% below its 50-day average ($39.64) and 0.8% below its 200-day average ($34.69). It has closed below the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 1 Jul 2026, 88 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
1 month: −12.6% (SPY −1.6%, XLV +13.5%). 3 months: −10.0% (SPY −0.4%, XLV +15.5%). 1 year: +12.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: HRMY, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 decline of 7.0% was 4.0× its average daily move of 1.8% over the past year, and its largest one-day decline since 23 Feb 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
5.4M shares were sold short at the 15 Oct 2026 settlement, 9.3% of the 58.2M shares outstanding; covering them would take 6.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
4 Nov 2026 volume of 2.5M shares was 2.4× the average of the 30 sessions before it (1.0M), as the price fell 7.0%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
October 31, 2023
+19.43%October 13, 2023
−30.25%March 28, 2023
−25.78%